Last reviewed · How we verify
Doxorubicin hydrochloride liposome
Doxorubicin hydrochloride liposome is a Anthracycline chemotherapy agent (liposomal formulation) Small molecule drug developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. It is currently FDA-approved for Metastatic breast cancer, Ovarian cancer, Multiple myeloma. Also known as: Doxil, Caelyx®/Lipodox®, Doxorubicin Hydrochloride Liposomal injection 20 mg/10 mL, A.
Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity.
Doxorubicin hydrochloride liposome is a chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, delivered via liposomal nanoparticles to improve tumor targeting and reduce systemic toxicity. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.
At a glance
| Generic name | Doxorubicin hydrochloride liposome |
|---|---|
| Also known as | Doxil, Caelyx®/Lipodox®, Doxorubicin Hydrochloride Liposomal injection 20 mg/10 mL, A, PLD |
| Sponsor | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
| Drug class | Anthracycline chemotherapy agent (liposomal formulation) |
| Target | DNA topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Doxorubicin is an anthracycline chemotherapy drug that works by intercalating into double-stranded DNA and inhibiting topoisomerase II, leading to DNA strand breaks and cell death. The liposomal formulation encapsulates the drug in lipid nanoparticles, which preferentially accumulate in tumor tissues through the enhanced permeability and retention (EPR) effect, thereby increasing drug concentration at the tumor site while reducing exposure to healthy tissues and decreasing cardiotoxicity compared to free doxorubicin.
Approved indications
- Metastatic breast cancer
- Ovarian cancer
- Multiple myeloma
- Kaposi sarcoma
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Mucositis
- Alopecia
- Cardiotoxicity (reduced vs. free doxorubicin)
- Infusion reactions
- Hand-foot syndrome
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (PHASE1)
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (PHASE2)
- Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (PHASE3)
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doxorubicin hydrochloride liposome CI brief — competitive landscape report
- Doxorubicin hydrochloride liposome updates RSS · CI watch RSS
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Doxorubicin hydrochloride liposome
What is Doxorubicin hydrochloride liposome?
How does Doxorubicin hydrochloride liposome work?
What is Doxorubicin hydrochloride liposome used for?
Who makes Doxorubicin hydrochloride liposome?
Is Doxorubicin hydrochloride liposome also known as anything else?
What drug class is Doxorubicin hydrochloride liposome in?
What development phase is Doxorubicin hydrochloride liposome in?
What are the side effects of Doxorubicin hydrochloride liposome?
What does Doxorubicin hydrochloride liposome target?
Related
- Drug class: All Anthracycline chemotherapy agent (liposomal formulation) drugs
- Target: All drugs targeting DNA topoisomerase II
- Manufacturer: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Indication: Drugs for Ovarian cancer
- Indication: Drugs for Multiple myeloma
- Also known as: Doxil, Caelyx®/Lipodox®, Doxorubicin Hydrochloride Liposomal injection 20 mg/10 mL, A, PLD
- Compare: Doxorubicin hydrochloride liposome vs similar drugs
- Pricing: Doxorubicin hydrochloride liposome cost, discount & access